POSB135 Budget Impact Analysis of Brigatinib for First-line Treatment of Alk-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Italy

Abstract

Authors

D Urbinati P La Malfa F Demma R Viti H Cranmer LG Hernandez

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×